Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD


April 28, 2023

Disease burden in patients with type 2 diabetes is largely driven by the associated long-term complications, making glycemic control an invaluable treatment goal. In 2005, the first incretin-based agent was introduced into the type 2 diabetes treatment landscape to address postprandial glucose control. Incretin-based therapies work through modulation of gut-derived hormones that play a role in maintaining euglycemia and regulating hormones. Incretin-based therapy plays a major role in managing patients with type 2 diabetes and has become a popular choice for controlling blood glucose levels because of its glycemic efficacy, ease of use, and low risk for hypoglycemia.

How familiar are you with this therapeutic approach to type 2 diabetes? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.